<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967511</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-1118</org_study_id>
    <nct_id>NCT01967511</nct_id>
  </id_info>
  <brief_title>Defining the Basis of Fibromuscular Dysplasia (FMD)</brief_title>
  <acronym>DEFINE</acronym>
  <official_title>Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study has evolved and expanded since its inception. Originally the intent
      was to establish the functional, molecular and genetic profile of fibroblasts from
      Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects.
      While this remains among the objectives, the study has been expanded to undertake a fully
      powered cross-tissue systems genetics analysis of FMD, and now also the related
      arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection
      (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific aims

        -  Specific aim 1: To establish a library of fibroblasts, DNA, plasma and serum from
           patients with FMD, SCAD and CvAD and unaffected healthy control subjects.

        -  Specific aim 2: To perform a fully powered cross-tissue systems analysis of the key
           regulatory gene networks and disease drivers underlying FMD, SCAD and CvAD.

        -  Specific aim 3: To cross-compare the molecular and genomic profiles of FMD, SCAD and
           CvAD to establish the degree of biologic similarity among these disorders.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of regulatory gene networks</measure>
    <time_frame>single time point at study enrollment</time_frame>
    <description>The identification of regulatory gene networks, and their key drivers, underlying FMD, SCAD and CvAD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of molecular features</measure>
    <time_frame>single time point at study enrollment</time_frame>
    <description>To cross-compare the molecular features of FMD, SCAD and CvAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of genomic features</measure>
    <time_frame>single time point at study enrollment</time_frame>
    <description>To cross-compare the genomic features of FMD, SCAD and CvAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA sequencing</measure>
    <time_frame>single time point at study enrollment</time_frame>
    <description>To define and compare the genomic (RNA sequencing) profile of fibroblasts from FMD, SCAD and CvAD subjects versus healthy control subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating cytokine</measure>
    <time_frame>single time point at study enrollment</time_frame>
    <description>To define and compare the circulating cytokine profile of FMD versus healthy control subjects.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Fibromuscular Dysplasia</condition>
  <condition>Spontaneous Coronary Artery Dissection</condition>
  <condition>Cervical Artery Dissection</condition>
  <arm_group>
    <arm_group_label>FMD subjects</arm_group_label>
    <description>patients who fulfill standard diagnostic criteria for FMD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCAD subjects</arm_group_label>
    <description>patients who fulfill standard diagnostic criteria for SCAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CvAD subjects</arm_group_label>
    <description>patients who fulfill standard diagnostic criteria for CvAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fibroblasts and other cell lines generated under this protocol and all blood-derived
      specimens (plasma, serum, DNA) will be kept indefinitely in a secure clinical database or
      bio-repository (as appropriate).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Will enroll 200 FMD patients, 100 SCAD patients, and 100 CvAD patients at the Mount Sinai
        Hospital. 200 matched healthy controls will also be recruited to this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of any age and freely willing to participate. For patients &lt; 18 years of age
             consent will be via parents.

          -  Fluency in either English or Spanish.

          -  Signed, informed consent

          -  For FMD, SCAD or CvAD subjects - a clinical diagnosis of FMD, SCAD or CvAD with
             fulfillment of standard diagnostic criteria.

          -  For healthy controls - no clinical features of FMD, SCAD or CvAD and absence of any
             major ongoing systemic disease including any condition requiring hospitalization,
             immune suppression, intravenous or injected medications or that result in functional
             impairment in the performance of activities of daily living. Healthy controls will be
             matched to enrolled FMD patients on the basis of gender and approximate age (within a
             5 year window of another FMD subject).

        Exclusion Criteria:

          -  Patients who have co-morbidities which reduces life expectancy to one year.

          -  Patients with any solid organ or hematological transplantation, or those in whom
             transplantation is considered.

          -  Active autoimmune disease.

          -  Illicit drug use.

          -  HIV positive.

          -  Prior malignancy.

          -  Any other form of vascular disease, including other arteriopathy coronary artery
             disease or peripheral vascular disease

          -  Family history of arteriopathy other than FMD, SCAD or CvAD (e.g. Ehlers-Danlos
             syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Kovacic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Olin, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Kovacic, MD, PhD</last_name>
    <phone>212-241-7014</phone>
    <email>jason.kovacic@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffrey Olin, DO</last_name>
    <email>jeffrey.olin@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette King, ANP</last_name>
      <phone>212-241-9454</phone>
      <email>annette.king@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Jason Kovacic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Olin JW, Di Narzo AF, d'Escamard V, Kadian-Dodov D, Cheng H, Georges A, King A, Thomas A, Barwari T, Michelis KC, Bouchareb R, Bander E, Anyanwu A, Stelzer P, Filsoufi F, Florman S, Civelek M, Debette S, Jeunemaitre X, Björkegren JLM, Mayr M, Bouatia-Naji N, Hao K, Kovacic JC. A plasma proteogenomic signature for fibromuscular dysplasia. Cardiovasc Res. 2020 Jan 1;116(1):63-77. doi: 10.1093/cvr/cvz219.</citation>
    <PMID>31424497</PMID>
  </results_reference>
  <results_reference>
    <citation>Kiando SR, Tucker NR, Castro-Vega LJ, Katz A, D'Escamard V, Tréard C, Fraher D, Albuisson J, Kadian-Dodov D, Ye Z, Austin E, Yang ML, Hunker K, Barlassina C, Cusi D, Galan P, Empana JP, Jouven X, Gimenez-Roqueplo AP, Bruneval P, Hyun Kim ES, Olin JW, Gornik HL, Azizi M, Plouin PF, Ellinor PT, Kullo IJ, Milan DJ, Ganesh SK, Boutouyrie P, Kovacic JC, Jeunemaitre X, Bouatia-Naji N. PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. PLoS Genet. 2016 Oct 28;12(10):e1006367. doi: 10.1371/journal.pgen.1006367. eCollection 2016 Oct.</citation>
    <PMID>27792790</PMID>
  </results_reference>
  <results_reference>
    <citation>Adlam D, Olson TM, Combaret N, Kovacic JC, Iismaa SE, Al-Hussaini A, O'Byrne MM, Bouajila S, Georges A, Mishra K, Braund PS, d'Escamard V, Huang S, Margaritis M, Nelson CP, de Andrade M, Kadian-Dodov D, Welch CA, Mazurkiewicz S, Jeunemaitre X; DISCO Consortium, Wong CMY, Giannoulatou E, Sweeting M, Muller D, Wood A, McGrath-Cadell L, Fatkin D, Dunwoodie SL, Harvey R, Holloway C, Empana JP, Jouven X; CARDIoGRAMPlusC4D Study Group, Olin JW, Gulati R, Tweet MS, Hayes SN, Samani NJ, Graham RM, Motreff P, Bouatia-Naji N. Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. J Am Coll Cardiol. 2019 Jan 8;73(1):58-66. doi: 10.1016/j.jacc.2018.09.085.</citation>
    <PMID>30621952</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cross-sectional study</keyword>
  <keyword>Fibromuscular dysplasia</keyword>
  <keyword>Fibroblast</keyword>
  <keyword>Spontaneous Coronary Artery Dissection</keyword>
  <keyword>Cervical Artery Dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
    <mesh_term>Fibromuscular Dysplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

